Introduction {#s1}
============

Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is recognised as an acute and fatal episode of respiratory deterioration of unidentifiable cause \[[@C1]--[@C5]\]. The mortality of AE of IPF (AE-IPF) is \>50% \[[@C3], [@C6]\], and AE profoundly affects the survival of patients with IPF; therefore, defining the clinical manifestations and pathogenesis of AE is crucial for improving the prognosis of IPF.

AE is characterised by new bilateral ground-glass opacities (GGOs) and/or consolidation superimposed on chronic interstitial pneumonia detected on high-resolution computed tomography (HRCT). HRCT indices, such as disease extent and radiological patterns at the time of AE diagnosis, are significant predictors of mortality in AE-IPF \[[@C7]--[@C10]\], acute respiratory distress syndrome (ARDS) \[[@C11]\] and acute interstitial pneumonia (AIP) \[[@C12]\], all of which have similar pathological characteristics of diffuse alveolar damage (DAD) \[[@C13]\]. In addition to the disease extent and the radiological patterns observed on HRCT, the asymmetrical distribution of disease has been analysed in the chronic phase of IPF \[[@C14]\]. Although IPFs are essentially bilateral and are often diffuse, a finding of asymmetry on HRCT could provide new insight into the pathogenesis of IPF and provide clinicians with prognostic information. However, the clinical relevance of an asymmetrical disease distribution has not been investigated in AE-IPF.

Therefore, in the present study, we aimed to elucidate the impact of an asymmetrical distribution of disease on outcomes in patients with AE-IPF. We used the HRCT indices obtained at the time of AE diagnosis to assess the extent and distribution of disease, and we investigated the prognostic value of these HRCT indices and that of other clinical parameters.

Materials and methods {#s2}
=====================

Study subjects {#s2a}
--------------

The medical records of all patients with IPF who required emergent hospitalisation at the Departments of Respiratory Medicine of Kyoto University Hospital and Tenri Hospital, from January 2006 to July 2013, were retrospectively analysed. IPF was diagnosed according to the American Thoracic Society/European Respiratory Society diagnostic criteria for IPF \[[@C15]\]. Patients were excluded if they had active neoplasms or did not undergo HRCT on admission. In total, 59 patients who met the diagnostic criteria for AE were included in the present study. The Kyoto University Hospital Institutional Review Board approved the present study (approval no. E2156/R0637).

Diagnostic criteria for acute exacerbations of idiopathic pulmonary fibrosis {#s2b}
----------------------------------------------------------------------------

AE-IPF was diagnosed as follows \[[@C3], [@C4]\]: 1) either a previous or concurrent diagnosis of IPF; 2) unexplained worsening or development of dyspnoea within 30 days; 3) HRCT with new bilateral GGOs and/or consolidation superimposed on background reticulation or honeycombing; 4) no evidence of pulmonary infection by bronchoalveolar lavage (BAL), endotracheal aspiration or other clinical evaluations; and 5) the exclusion of alternative causes, such as left heart failure, pulmonary embolism and identifiable causes of acute lung injury. Without BAL or endotracheal aspiration, pulmonary infection was excluded only when 1) no purulent sputum was detected, 2) the sputum or blood culture was negative, 3) urinary antigen tests for pneumococcus and *Legionella* were negative, 4) serum β-D-glucan levels were normal, 5) serum cytomegalovirus antigen was undetected and 6) HRCT images lacked the predominance of segmental opacities.

Data collection and clinical evaluation {#s2c}
---------------------------------------

Clinical information was retrospectively collected from medical records. All of the patients underwent blood testing and surveillance for infection on admission. BAL was performed using the recommended procedure \[[@C16], [@C17]\]. Survival at 180 days was assessed as the primary outcome.

High-resolution computed tomography evaluation {#s2d}
----------------------------------------------

All of the patients underwent chest HRCT before AE treatment was initiated. Three independent observers (A.S., T.K. and K.T.) who were blinded to the patients\' clinical information reviewed the HRCT images. The images were assessed for GGOs, consolidation, reticulation (intralobular reticular opacification and interlobular septal thickening) and honeycombing, and emphysema. To measure the disease extent semi-quantitatively, the lung fields on each side were divided into the following five zones: at the level of the origin of the great vessels, the mid-arch of the aorta, the carina, the pulmonary venous confluence, and 10 mm above the top of the right hemi-diaphragm \[[@C14], [@C18]\]. The extents of GGO, consolidation, reticulation and honeycombing, and emphysema were scored to the nearest 10% in the 10 lung zones; these scores were subsequently averaged to obtain the mean scores. GGOs and consolidation accounting for new lesions were grouped as parenchymal opacities, and reticulation and honeycombing were grouped as fibrotic abnormalities. To assess the asymmetries of GGOs and consolidation, the right-to-left ratio of parenchymal opacities was calculated. When the ratio was ≥2.0 or ≤0.5, the patient was diagnosed with asymmetrical AE ([figure 1](#F1){ref-type="fig"}). The presence or absence of bronchiectasis in parenchymal opacities was also assessed in each case.

![Evaluation by high-resolution computed tomography (HRCT). The extents of emphysema, ground-glass opacities (GGOs), consolidation, and reticulation and honeycombing (R/HC) were scored to the nearest 10% in each of the five HRCT slices. The scores of 10 zones were averaged to obtain the mean scores for each lung. The right-to-left ratio of the parenchymal opacities consisting of GGOs and consolidation was calculated. This case, in which the ratio was 0.42, was an example of asymmetrical acute exacerbation.](00036-2016.01){#F1}

Statistical analyses {#s2e}
--------------------

The statistical analyses were performed using JMP, version 10.0 (SAS Institute Inc., Cary, NC, USA). All statistical variations in the quantitative data are expressed as the mean±[sd]{.smallcaps}, and p\<0.05 was considered statistically significant. Comparisons between the groups were performed using either Fisher\'s exact test or the Mann--Whitney U test, as appropriate. To define the prognostic value of each variable at diagnosis, a survival analysis of the initial 180 days was performed using the Cox proportional hazards model.

Variables were entered into a multivariate analysis model only when they had p-values ≤0.10 in the preceding univariate analyses. The 180-day mortality was calculated, and survival curves were generated using the Kaplan--Meier method and were compared between groups using the log-rank test.

Results {#s3}
=======

Clinical characteristics {#s3a}
------------------------

The study included 59 patients with IPF. The clinical data obtained at the time of AE diagnosis and the outcomes are presented in [table 1](#TB1){ref-type="table"}. The mean age was 71.7 years, and 54 of the patients (91.5%) were male. BAL was performed in 11 patients (18.6%).

###### 

Patient characteristics and clinical data

  **Characteristic**                           
  -------------------------------------------- -------------
  **Subjects n**                                    59
  **Males**                                      54 (91.5)
  **Age years**                                  71.7±8.2
  **Smoking history**                            49 (86.0)
  **FVC before AE % predicted**                  71.0±21.9
  ***D*L**~**CO**~ **before AE % predicted**     37.0±17.3
  **Treatment before AE**                      
   LTOT                                          23 (39.0)
   Corticosteroids                               20 (33.9)
   Immunosuppressive agents                      10 (16.9)
  **WBC µL^−1^**                                10 490±4150
  **D-dimer µg·mL^−1^**                           5.1±6.3
  **CRP mg·dL^−1^**                               6.5±6.4
  **LDH IU·L^−1^**                                380±226
  **KL-6 U·mL^−1^**                              1763±1278
  **P/F\<200**                                   26 (47.3)
  **BAL performed**                              11 (18.6)
  **Treatment of AE**                          
   High-dose corticosteroids                     59 (100)
   Antibiotics                                   58 (98.3)
   Immunosuppressive agents                      30 (50.8)
   Noninvasive ventilation                       14 (23.7)
  **180-day mortality %**                          59.2

The data are presented as mean±[sd]{.smallcaps} or n (%), unless otherwise indicated. FVC: forced vital capacity; AE: acute exacerbation; *D*L~CO~: diffusing capacity of the lung for carbon monoxide; LTOT: long-term oxygen therapy; WBC: white blood cell; CRP: C-reactive protein; LDH: lactate dehydrogenase; KL-6: Krebs von den Lungen-6; P/F: the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen; BAL: bronchoalveolar lavage.

High-resolution computed tomography indices at diagnosis of an acute exacerbation {#s3b}
---------------------------------------------------------------------------------

The HRCT indices at the time of an AE diagnosis are presented in [table 2](#TB2){ref-type="table"}. The mean extent of the parenchymal opacities reflecting the extent of GGOs and consolidation was 40.5%, whereas the mean extent of reticulation and honeycombing was 14.8%. Asymmetrical AE was observed in 13 patients (22.0%).

###### 

Chest high-resolution computed tomography indices at diagnosis

  **Indices**                                    **Extent or number**
  --------------------------------------------- ----------------------
  **Parenchymal opacities %**                         40.5±15.1
  **Ground-glass opacities %**                        34.1±15.1
  **Consolidation %**                                  6.4±7.6
  **Reticulation/honeycombing %**                     14.8±12.1
  **Emphysema %**                                      7.0±10.2
  **Bronchiectasis in parenchymal opacities**         28 (47.5)
  **Asymmetrical acute exacerbation**                 13 (22.0)

The data are presented as mean±[sd]{.smallcaps} or n (%).

Therapeutic regimens and outcomes {#s3c}
---------------------------------

Following the diagnosis of AE, almost all of the patients received high-dose corticosteroids and antibiotics simultaneously ([table 1](#TB1){ref-type="table"}). The 180-day mortality was 59.2%.

The prognostic factors for 180-day mortality {#s3d}
--------------------------------------------

The results of the univariate and multivariate analyses of the predictors of 180-day mortality are provided in [table 3](#TB3){ref-type="table"}. The univariate analyses revealed that long-term oxygen therapy (LTOT) prior to the diagnosis of AE, level of serum lactate dehydrogenase (LDH) and asymmetrical AE were associated with 180-day mortality. Following the multivariate analysis, LTOT, LDH (10 IU·L^−1^ per unit) and asymmetrical AE remained significant (LTOT, hazard ratio 2.34, 95% CI 1.04--5.28, p=0.04; LDH, hazard ratio 1.02, 95% CI 1.00--1.05, p=0.02; asymmetrical AE, hazard ratio 0.36, 95% CI 0.10--0.99, p=0.047), whereas the extent of GGOs and consolidation was not a predictor of 180-day mortality. The estimated 180-day mortality of the patients with asymmetrical AE was significantly lower than that of the patients with symmetrical AE (asymmetrical AE 30.8% *versus* symmetrical AE 68.2%; p=0.03) ([figure 2](#F2){ref-type="fig"}).

###### 

Univariate and multivariate analyses of 180-day mortality

                                                 **Univariate analysis**   **Multivariate analysis**                                 
  --------------------------------------------- ------------------------- --------------------------- ---------- ------ ------------ ---------
  **Age**                                                 1.00                    0.95--1.05             0.96                        
  **Male**                                                1.97                    0.59--12.2             0.30                        
  **Smoking history**                                     0.44                    0.20--1.11             0.08     0.51   0.23--1.31    0.15
  **LTOT**                                                2.10                    1.06--4.25            0.03\*    2.34   1.04--5.28   0.04\*
  **FVC before AE % predicted**                           0.99                    0.97--1.01             0.43                        
  ***D*L**~**CO**~ **before AE % predicted**              0.98                    0.94--1.01             0.16                        
  **P/F \<200**                                           0.69                    0.33--1.40             0.30                        
  **CRP**                                                 1.03                    0.96--1.95             0.36                        
  **LDH 10 IU·L^−1^ per unit**                            1.02                    1.01--1.03           \<0.01\*   1.02   1.00--1.05   0.02\*
  **KL-6 100 U·mL^−1^ per unit**                          1.02                    1.00--1.04             0.10     0.99   0.96--1.02    0.69
  **Parenchymal opacities**                               1.02                    1.00--1.04             0.09     0.99   0.96--1.02    0.51
  **Ground-glass opacities**                              1.01                    0.99--1.03             0.27                        
  **Consolidation**                                       1.02                    0.98--1.06             0.26                        
  **Reticulation/honeycombing**                           0.98                    0.95--1.02             0.31                        
  **Emphysema**                                           1.02                    0.98--1.05             0.34                        
  **Bronchiectasis in parenchymal opacities**             1.19                    0.60--2.38             0.62                        
  **Asymmetrical AE**                                     0.33                    0.10--0.85            0.02\*    0.36   0.10--0.99   0.047\*

HR: hazard ratio; LTOT: long-term oxygen therapy; FVC: forced vital capacity; AE: acute exacerbation; *D*L~CO~: diffusing capacity of the lung for carbon monoxide; P/F: the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen; CRP: C-reactive protein; LDH: lactate dehydrogenase; KL-6: Krebs von den Lungen-6. \*: p\<0.05.

![A comparison of 180-day survival curves between patients with idiopathic pulmonary fibrosis with asymmetrical acute exacerbation (AE) and those with symmetrical AE.](00036-2016.02){#F2}

Comparison between asymmetrical and symmetrical acute exacerbations {#s3e}
-------------------------------------------------------------------

To define the clinical and radiological features of asymmetrical AE, asymmetrical and symmetrical AEs were compared ([table 4](#TB4){ref-type="table"}). Demographic characteristics, the most recently measured percentage of predicted forced vital capacity (FVC) before the diagnosis of AE, treatment and laboratory data, the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, the rates of BAL performance at the time of AE, and the therapeutic regimens following the diagnosis of AE were similar. HRCT performed at the diagnosis of AE revealed that GGOs and parenchymal opacities were less extensive in the asymmetrical AE group (asymmetrical AE 24.1±14.4% and 32.6±14.5% *versus* symmetrical AE 37.0±14.2% and 42.7±14.6%; p\<0.01 and 0.04, respectively).

###### 

Patient characteristics between asymmetrical and symmetrical acute exacerbation

                                                 **Asymmetrical AE**   **Symmetrical AE**   **p-value**
  --------------------------------------------- --------------------- -------------------- -------------
  **Subjects n**                                         13                    46          
  **Age years**                                       74.2±8.1              71.0±8.1           0.21
  **Male**                                            10 (76.9)            44 (95.7)           0.07
  **Smoking history**                                 3 (60.0)             21 (91.3)           0.14
  **FVC before AE % predicted**                       70.2±17.6            71.3±23.3           0.70
  ***D*L~CO~ before AE % predicted**                  34.6±20.5            38.0±16.2           0.32
  **Treatment before AE**                                                                  
   LTOT                                               4 (30.8)             19 (41.3)           0.54
   Corticosteroids                                    2 (15.4)             18 (39.1)           0.18
   Immunosuppressive agents                            0 (0.0)             10 (21.7)           0.10
  **WBC ×10^3^·µL^−1^**                              10 120±4720          10 590±4020          0.43
  **D-dimer µg·mL^−1^**                                4.7±5.3              5.3±6.7            1.00
  **CRP mg·dL^−1^**                                    5.7±4.6              6.7±6.8            0.96
  **LDH IU·L^−1^**                                     347±88               389±252            0.82
  **KL-6 U·mL^−1^**                                   1607±1074            1805±1335           0.54
  **P/F\<200**                                        8 (61.5)             18 (42.9)           0.34
  **BAL performed**                                    1 (7.7)             10 (21.7)           0.43
  **Parenchymal opacities %**                         32.6±14.5            42.7±14.6          0.04\*
  **Ground-glass opacities %**                        24.1±14.4            37.0±14.2         \<0.01\*
  **Consolidation %**                                  8.6±9.2              5.7±7.0            0.18
  **Reticulation/honeycombing %**                     16.5±11.3            14.3±12.4           0.41
  **Emphysema %**                                     11.7±13.1             5.7±9.0            0.07
  **Bronchiectasis in parenchymal opacities**         6 (47.5)             22 (47.8)           1.00
  **Treatment of AE**                                                                      
   High-dose corticosteroids                          13 (100)              46 (100)            --
   Antibiotics                                        13 (100)             45 (97.8)           1.00
   Immunosuppressive agents                           4 (30.8)             26 (56.5)           0.13
   Non-invasive ventilation                           3 (23.1)             11 (23.9)           1.00
  **180-day mortality %**                               30.8                  68.2            0.03\*

The data are presented as mean±[sd]{.smallcaps} or n (%), unless otherwise indicated. AE: acute exacerbation; FVC: forced vital capacity; *D*L~CO~: diffusing capacity of the lung for carbon monoxide; LTOT: long-term oxygen therapy; WBC: white blood cell; CRP: C-reactive protein; LDH: lactate dehydrogenase; KL-6: Krebs von den Lungen-6; P/F: the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen; BAL: bronchoalveolar lavage. \*: p\<0.05.

Discussion {#s4}
==========

An asymmetrical distribution of GGOs and consolidation was observed in 22.0% of patients at the diagnosis of AE-IPF. Asymmetrical AE was a significant predictor of a better outcome, even after adjusting for other possible prognostic factors. Asymmetrical AE was associated with less extensive GGOs, whereas other radiological and clinical features were similar between the patients with symmetrical and asymmetrical AEs.

An asymmetrical disease distribution in interstitial lung diseases has not been addressed, with the exception of a single study of chronic IPF \[[@C14]\]. T[cherakian]{.smallcaps} *et al*. reported that asymmetrical IPF, which was defined as asymmetrical fibrosis with a 1.5-fold greater extent in one lung than the other, was observed in some patients during the chronic phase \[[@C14]\]. The authors revealed that asymmetrical IPF was associated with gastro-oesophageal reflux disease (GERD) and a higher incidence of AE, suggesting the clinical relevance of asymmetry in interstitial lung diseases. However, asymmetrical distributions on HRCT have not been assessed in AE-IPF, AIP or ARDS. The present study was the first to address asymmetry in AE-IPF and elucidate the clinical implications of asymmetrical AE. Our findings have raised three possible hypotheses regarding the relationship between asymmetrical AE and improved outcomes.

First, asymmetrical AE may represent an earlier phase of AE, before the lesions extend and become both symmetrical and diffuse. Preceding HRCT studies of AE-IPF revealed that more extensive lesions in the late and proliferative stages increased the risk of a worse prognosis \[[@C8]\], highlighting the potential impact of a delay in diagnosis \[[@C19]\]. The better prognoses associated with asymmetrical AE may be related to the earlier detection of AE during the asymmetrical phase and the subsequent implementation of immediate therapeutic interventions.

Second, asymmetrical AE may be a phenotype that is distinct from symmetrical AE. A[kira]{.smallcaps} *et al*. reported that peripheral patterns of AE-IPF did not evolve into diffuse patterns, whereas multifocal patterns represented an early manifestation of a diffuse pattern \[[@C7]\], suggesting the existence of at least two different phenotypes of AE-IPF. Additionally, the histopathology of AE is characterised by DAD and organising pneumonia (OP) superimposed on fibrotic interstitial pneumonia \[[@C20], [@C21]\]. OP lesions are generally more localised than DAD; therefore, the asymmetrical distribution of GGOs and consolidation may reflect the predominance of OP lesions. Such different pathological features may affect the disease distribution, responses to treatment and outcomes.

Third, asymmetrical AE may reflect locoregional factors such as GERD and unidentified infections. In asymmetrical IPF, the first AE is virtually unilateral and more frequently occurs in the affected lung \[[@C14]\], suggesting the role of GERD in both chronic fibrosis and AE. Another potential locoregional factor is unidentified infection. Although bilateral infectious deteriorations of IPF were reported to have poor outcomes similar to those of non-infectious AE \[[@C22]\], unidentified infectious agents may affect the outcome of AE-IPF \[[@C3], [@C23]\]. We made every effort to exclude infectious causes in the diagnosis of AE in this cohort; however, the possibility of unidentified infection remained. Furthermore, the extent of emphysema in patients with asymmetrical AE was higher than in patients with symmetrical AE. Ventilation-perfusion mismatch due to emphysema may affect the asymmetrical distribution, although the extent of emphysema itself was not associated with mortality.

Previous studies revealed that the presence of a diffuse pattern, lesion extent, HRCT score and centrilobular emphysema on HRCT may be prognostic factors for mortality among patients with AE-IPF and IIPs \[[@C7]--[@C9]\]. A[kira]{.smallcaps} *et al*. found that in AE-IPF, a poorer prognosis was associated with a diffuse pattern compared with either a peripheral or a multifocal pattern \[[@C7]\]. F[ujimoto]{.smallcaps} *et al*. adapted the HRCT scoring system \[[@C8]\], which had been used previously to predict the prognosis in ARDS and AIP to AE-IPF \[[@C12], [@C24]\], and they demonstrated that HRCT scores and the extent of GGOs with traction bronchiectasis and honeycombing were associated with increased mortality \[[@C8]\]. These preceding studies and ours suggest the prognostic value of HRCT assessment at the time of AE diagnosis, and our results also indicate the need to evaluate the asymmetrical distribution of disease in the acute phase of IPF.

Some limitations of the present study should be mentioned. First, only 18.6% of the patients underwent BAL at the time of diagnosis, although the proportion of patients who underwent BAL did not differ according to the clinical group, the presence of asymmetrical AE or patient outcomes. The latest diagnostic criteria for AE-IPF include cases with underlying triggers, such as infection and surgery (triggered AE), as well as those without triggers (idiopathic AE) \[[@C25]\]. While the present study excluded cases with apparent triggers, such as pneumonia, the clinical implications of asymmetrical distribution should be re-evaluated under this more comprehensive concept of AE. Second, we evaluated bronchiectasis in parenchymal opacities in five slices. The prevalence may have been underestimated because traction bronchiolectasis or bronchiectasis with GGO or consolidation was originally assessed for zones of each lung \[[@C8], [@C12]\].

Despite these limitations, we have demonstrated the clinical relevance of an asymmetrical distribution for the diagnosis of AE-IPF. Among the HRCT indices recorded at the time of diagnosis, asymmetrical AE predicts better outcomes. Attention should be paid to both asymmetry and disease extent on HRCT because these factors can provide additional clues for a better understanding of AE-IPF and a more precise prediction of its course.
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